Russell Investments Group Ltd. Sells 123,756 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Russell Investments Group Ltd. trimmed its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 35.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 226,273 shares of the company's stock after selling 123,756 shares during the period. Russell Investments Group Ltd. owned about 0.49% of Pacira BioSciences worth $7,634,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. lifted its stake in shares of Pacira BioSciences by 96.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,185 shares of the company's stock worth $36,000 after buying an additional 583 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Pacira BioSciences by 310.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,001 shares of the company's stock worth $61,000 after purchasing an additional 1,514 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Pacira BioSciences by 63.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,481 shares of the company's stock valued at $137,000 after purchasing an additional 1,736 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in Pacira BioSciences by 9.4% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,103 shares of the company's stock valued at $157,000 after acquiring an additional 438 shares during the period. Finally, Trust Point Inc. acquired a new position in Pacira BioSciences in the fourth quarter worth about $245,000. Institutional investors and hedge funds own 99.73% of the company's stock.

Insiders Place Their Bets

In other Pacira BioSciences news, Director Gary W. Pace sold 90,000 shares of Pacira BioSciences stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $30.60, for a total value of $2,754,000.00. Following the completion of the sale, the director now owns 22,127 shares in the company, valued at approximately $677,086.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Pacira BioSciences news, Director Gary W. Pace sold 1,066 shares of Pacira BioSciences stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total value of $31,628.22. Following the transaction, the director now owns 140,384 shares in the company, valued at $4,165,193.28. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Gary W. Pace sold 90,000 shares of the stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the completion of the transaction, the director now directly owns 22,127 shares of the company's stock, valued at approximately $677,086.20. The disclosure for this sale can be found here. Company insiders own 6.60% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. TheStreet upgraded Pacira BioSciences from a "d+" rating to a "c" rating in a research report on Thursday, February 29th. HC Wainwright reiterated a "buy" rating and set a $57.00 target price on shares of Pacira BioSciences in a research report on Wednesday. Needham & Company LLC reduced their price target on shares of Pacira BioSciences from $45.00 to $43.00 and set a "buy" rating on the stock in a research report on Wednesday. Wedbush reaffirmed an "outperform" rating and set a $57.00 price objective on shares of Pacira BioSciences in a report on Thursday, February 8th. Finally, JPMorgan Chase & Co. started coverage on Pacira BioSciences in a research report on Thursday, March 7th. They set an "overweight" rating and a $45.00 price target on the stock. Eleven research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $47.40.

Pacira BioSciences Trading Up 11.8 %

Shares of NASDAQ:PCRX traded up $3.14 during trading on Wednesday, hitting $29.65. 1,961,053 shares of the company's stock were exchanged, compared to its average volume of 507,365. The firm has a 50-day moving average price of $28.28 and a two-hundred day moving average price of $29.51. The company has a current ratio of 5.24, a quick ratio of 4.17 and a debt-to-equity ratio of 0.59. The firm has a market cap of $1.38 billion, a P/E ratio of 37.15 and a beta of 0.77. Pacira BioSciences, Inc. has a 1-year low of $25.33 and a 1-year high of $43.50.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its quarterly earnings data on Thursday, February 29th. The company reported $0.71 EPS for the quarter, hitting analysts' consensus estimates of $0.71. Pacira BioSciences had a net margin of 6.22% and a return on equity of 12.81%. The business had revenue of $181.24 million for the quarter, compared to analyst estimates of $180.60 million. Equities analysts predict that Pacira BioSciences, Inc. will post 2.17 earnings per share for the current year.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.